project id: TCGA-BRCA; case submitter id: TCGA-AR-A24K; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; concentration: 0.17; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.7; rna integrity number: 9.3; spectrophotometer method: UV Spec; age at index: 46; days to birth: -16961; ethnicity: not reported; gender: female; race: white; vital status: Alive; year of birth: 1958; age at diagnosis: 16961; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage IIA; ajcc pathologic t: T2; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1548.0; icd 10 code: C50.9; last known disease status: not reported; morphology: 8500/3; primary diagnosis: Infiltrating duct carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Breast, NOS; synchronous malignancy: No; tissue or organ of origin: Breast, NOS; tumor grade: Not Reported; year of diagnosis: 2004; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2325; days to sample procurement: 0; initial weight: 200.0; portion submitter id: TCGA-AR-A24K-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;